Emerging Markets Earnings: Teva Moves On With Russia, LatAm In Focus
This article was originally published in PharmAsia News
Teva appears to have eased past a management shakeup and extended its lead in Copaxone with the company ready to expand in emerging markets as the next frontier, led by Russia and Latin America.
You may also be interested in...
Teva’s recent restricting has the firm focusing internal R&D on CNS and respiratory therapies, with plans to out-license or creatively finance development of non-core pipeline assets.
With the imminent possibility of generic competition to Copaxone, Teva looks to move 65% of current patients to its thrice-weekly version by the end of 2014.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.